{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Santamaria PG"],"funding":["Worldwide Cancer Research","Instituto de Salud Carlos III"],"pagination":["E676"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6571660"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(5)"],"pubmed_abstract":["Therapy resistance is responsible for tumour recurrence and represents one of the major challenges in present oncology. Significant advances have been made in the understanding of the mechanisms underlying resistance to conventional and targeted therapies improving the clinical management of relapsed patients. Unfortunately, in too many cases, resistance reappears leading to a fatal outcome. The recent introduction of immunotherapy regimes has provided an unprecedented success in the treatment of specific cancer types; however, a good percentage of patients do not respond to immune-based treatments or ultimately become resistant. Cellular plasticity, cancer cell stemness and tumour heterogeneity have emerged as important determinants of treatment resistance. Epithelial-to-mesenchymal trans"],"journal":["Journal of clinical medicine"],"pubmed_title":["Contribution of Epithelial Plasticity to Therapy Resistance."],"pmcid":["PMC6571660"],"funding_grant_id":["16-0295","12-1057","CIBERONC 16/12/00295","PI16/00134"],"pubmed_authors":["Santamaria PG","Moreno-Bueno G","Cano A"],"additional_accession":[]},"is_claimable":false,"name":"Contribution of Epithelial Plasticity to Therapy Resistance.","description":"Therapy resistance is responsible for tumour recurrence and represents one of the major challenges in present oncology. Significant advances have been made in the understanding of the mechanisms underlying resistance to conventional and targeted therapies improving the clinical management of relapsed patients. Unfortunately, in too many cases, resistance reappears leading to a fatal outcome. The recent introduction of immunotherapy regimes has provided an unprecedented success in the treatment of specific cancer types; however, a good percentage of patients do not respond to immune-based treatments or ultimately become resistant. Cellular plasticity, cancer cell stemness and tumour heterogeneity have emerged as important determinants of treatment resistance. Epithelial-to-mesenchymal trans","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2025-04-22T02:41:02.276Z","creation":"2019-07-24T07:19:10Z"},"accession":"S-EPMC6571660","cross_references":{"pubmed":["31091749"],"doi":["10.3390/jcm8050676"]}}